Trials / Recruiting
RecruitingNCT07517198
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Conditions
- Solid Tumor
- Small Cell Lung Cancer (SCLC)
- High Grade Neuroendocrine Cancer
- Small Cell Carcinomas of Non-lung Origin
- Non-small Cell Lung Cancer (NSCLC)
- Prostate Cancer
- Ovarian Cancer
- Renal Carcinoma (Clear and Non-clear Cell)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Hepatic Cancer
- Gastric Cancer
- Triple-negative Breast Cancer (TNBC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EXS74539 | Oral administration |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
- First posted
- 2026-04-08
- Last updated
- 2026-04-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07517198. Inclusion in this directory is not an endorsement.